Company intelligence / Profile preview

Theragene Pharmaceuticals

San Diego, California, United Statestheragenepharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Currently developing SERCA 2a gene therapy (Mydicar®) for heart failure and cardiomyopathies. Phase I/II trials have demonstrated safety and efficacy, with recent enrollment completion in the MUSIC-HFrEF trial as of March 2025[8][9].

Therapeutic areas: OncologyCardiovascular
Modalities: Gene therapyImmunotherapy
Industry: Biotech

Drug pipeline

1 asset

Mydicar

Phase 2

Indications: Cardiovascular disease

Partnerships

SardocorEiger BioPharmaceuticals (acquired Mydicar® from them)

Beyond the preview

Go deeper on Theragene Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragene Pharmaceuticals.

Explore the full profile